| Bioactivity | GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption[1][2]. |
| Invitro | GRGDSPK TFA (EMD 56574 TFA; RGD; 0.1-50 μM; for 4 days) inhibits mineralization in a dose-dependent manner as determined by measuring calcium content and 70 bonehnit area of tissue in parietal bones 18 days old isolated from pregnant Sprague-Dawley rats[1]. GRGDSPK TFA (10, 50 μM; for 4 days) dramatically alteres bone morphology, with a disruption of osteoblast and mineralized matrix organization[1]. GRGDSPK TFA (RGD; 250 μM), added to the medium, effectively blocks integrin-fibronectin binding and significantly increases the average size of wild-type cell aggregates[2]. When GRGDSPK TFA (250 μM) is added, wild-type mesendodermal progenitors exhibits strongly reduced adhesion forces and work, indicating that the detachment parameters recorded are specific for fibronectin and that integrins expressed in mesendodermal progenitors are involved[2]. GRGDSPK TFA (RGD-containing, 1.5 mM, 1.0 mM, and 0.5 mM) and RGD-mod-ified peptides impair the ability of sperm to fertilizebovine oocytes, illustrated by a reduction in cleavage in a dose-dependent manner[3]. |
| Name | GRGDSPK TFA |
| Sequence | Gly-Arg-Gly-Asp-Ser-Pro-Lys |
| Shortening | GRGDSPK |
| Formula | C30H50F3N11O13 |
| Molar Mass | 829.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |